Let's walk it back to the basics.

Most prostate cancer needs testosterone as a signal to reproduce, at least initially (sometimes it evolves to ability to reproduce without it; that's called "castrate-resistant prostate cancer").

Reducing testosterone, either through an orchiectomy (physical castration) or androgen-deprivation therapy (ADT, aka "chemical castration") is a first line of defense to slow or stop prostate cancer spread.

Low testosterone — however triggered — comes with a range of potential undesirable side-effects, including bone and muscle density loss, hot flushes, low energy, mood swings, weight gain, reduction in sex drive, gynocomastia (breast development), and elevated risks of diabetes, heart disease, and stroke. Many of these are similar to menopause symptoms in women, and not all of them will happen to every patient.

Traditionally, ADT has been administered by an injection every 1–3 months, which can sometimes cause short-term acute symptoms (swelling, rashes, muscle ache, flu-like symptoms) in addition to the longer-term, chronic testosterone-deprivation symptoms I listed above.

Orgovyx has all the same long-term chronic side-effects as the other ADT medications, but comes in a daily microdose as a pill, so it doesn't cause the acute symptoms that injections do, and leaves your body more quickly when you stop. And unlike some injectibles like Lupron, it starts working right away, without an initial testosterone surge that can temporarily accelerate cancer spread.

That's why Orgovyx is considered the "latest and greatest" as far as ADT is concerned, but ADT in general is not the only approach for treating prostate cancer. There are many other treatments they can add on top of it, depending on the patient's cancer status, age, health, genetic background, and (most importantly) personal choices.

I hope this helps to set some context.